About our project

The problem we solve: Root canal treatments fail in 50% of cases, leading to persistent infections, antibiotic overuse, pain, repeated procedures, and increased healthcare costs.

About our solution: Cementic developed EndoNu™, an innovative nano-bioceramic root canal sealer that eliminates 99.9% of bacteria, actively rebuilds dentine, and releases antiseptics continuously, reducing root canal failures by half.

Progress to date:

Cementic has developed a pilot batch ( final product at scale), EndoNu™, validated through extensive preclinical studies demonstrating its safety and superior antimicrobial efficacy. We completed successful biocompatibility and ISO 10993 evaluations, preparing for regulatory submissions. Strategic partnerships are established with leading dental distributors including Henry Schein, and collaborations are underway with key dental manufacturers like FKG and Produits Dentaires. The dental and scientific community has strongly welcomed our innovation, highlighted by positive feedback, interest from industry experts, and publications in top dental journals.

About Our Company

How We Help Patients

Cementic's innovation directly improves patients' long-term health by significantly reducing root canal failures—a common source of chronic infections and antibiotic overuse. By using advanced bioceramic technology with targeted antiseptic release, our solution eliminates harmful bacteria, promotes natural healing, and helps patients avoid painful, costly retreatments or implants. With healthier teeth and reduced infections, patients can maintain overall better systemic health and quality of life.

How We Help Physicians

Cementic’s innovation addresses a key frustration for dentists: repeated root canal failures negatively impact patient trust, satisfaction, and practice reputation. By leveraging nano-bioceramic technology and sustained antiseptic delivery, Cementic’s EndoNu™ significantly reduces reinfection and retreatment rates, ensuring predictable clinical outcomes. This allows dentists to provide reliable, high-quality care, enhancing their professional reputation, patient satisfaction, and practice growth.

How We Help Hospitals

Each year $40B is spent on root canals in the USA.  Cementic’s EndoNu™ benefits hospitals and dental institutions by significantly decreasing the rate of root canal failures, a costly and resource-intensive challenge. Failed treatments often lead to complications requiring additional clinical interventions, antibiotic treatments, and complex implant surgeries. Hospitals can thus improve patient outcomes, reduce antibiotic usage, optimize treatment efficiency, lower procedural costs, and enhance their institutional reputation for excellence and innovation.

How We Help Partners

Cementic helps partners solve key business challenges: dental suppliers and distributors face increasing pressure to deliver innovative solutions in a highly competitive market ( from abroad). By partnering with Cementic, they gain exclusive access to advanced, evidence-based technology, which increases their market differentiation, customer loyalty, and profitability. Hospitals and clinics benefit from improved operational efficiency, fewer repeat procedures, and enhanced patient satisfaction—addressing core institutional pain points.

Innovation Details

Intellectual Property Summary

Write and filed the core patent in 2017 : Protect LNPs formulation + antiseptic+ Root canal sealer

Write and filed a new patent in 2024 : Protect Nano powder with nano-Hydryapatite  ( Nasa Compound)

Patent Link
https://uspto.report/patent/app/20200315923

Clinical Information

We do not yet have clinical data for Cementic's technology; however, our extensive preclinical studies provide strong evidence of efficacy. Specifically, our ex vivo studies using extracted human teeth have demonstrated impressive antimicrobial performance, with significant bacterial load reduction within root canals. Importantly, the conditions in ex vivo root canal studies closely approximate those found clinically, as treated teeth lack active blood circulation and immune response, making our results highly indicative of real-world effectiveness.

Moreover, existing literature from King's College London supports the principle that reducing bacterial load significantly enhances clinical success  (Zahran et al., King's College London, 2021).

We are currently in the regulatory preclinical stage, preparing for FDA submission under the 510(k) pathway, which does not require a clinical study (strong predicate). However a clincal study is planned in Europe to get the CE mark and to prove the superiority of our product. Any input on structuring and getting data from US patients in 2026 to avoid a clinical study in Europe will be helpful. 

Regulatory Status

Biocompatibility testing made by Eurofins ( last result for September 25)

ISO 13485 certification scheduled for August 25.

USA ( funded) : 510 K , reviewed with MCRA consulting ( Former FDA director in dental department) . 

CE mark ( not funded): After a 1-year clinical study to demonstrate the safety and superiority of our product => to get health insurance reimbursement. 

How we will use the funds raised

- Operational cost: Produce 1 GMP batch and 1 commercial batch. Commercialization in the USA includes 2 additional commercial batches (we have an LOI from Henry Schein).

- R&D: Internalize part of the production to manage COGS and conduct the clinical study

- Team: RA/QA director, business developer, production engineer, R&D assistant.

- Operational cost: Production of 1 GMP batch and 1 commercial batch, Commercialization in the USA with 2 additional commercial batch  ( we have an LOI from Henry Shein) 

- R&D : Internalize part of the production to manage the COGS, Clinical Study, 

- Team : RA/QA director , Business Developer, Production engineer , R&D assistant

Thank You

Root canal failure causes real pain, infections, and unnecessary antibiotic use and implants for millions. We're dedicated to making that happen by applying biotech and nanotech to dramatically improve patient care. Your support and vote on MedStartr will help us transform dentistry for patients and dentists alike. Together, we can make a meaningful difference and end a public health issue forever. 

Investor Info

Market Size

The global endodontics market (root canal therapy and related products) is large andsteadily growing. In 2025, the market for root canal treatment materials is estimated at ~$2.5billion globally and is projected to reach ~$3.25 billion by 2030 (4.8% CAGR). Within this,Cementic’s initial focus is on the consumable root canal sealer segment in key regions(North America and Europe), roughly a $350 million/year serviceable market. The root canal market is one of the fastest-growing segments, projected to reach $1.2 billion by 2030. Thissegment encompasses over 80 million procedures per year that could directly benefit fromEndoNu™’s superior infection control.

Projected 3 Year Growth

Numbers are derived from a Business Case made with FKG SA ( market penetration of FKG SA, if Henry Shein distribute higher numbers are expected) 

Revenue Model

Cementic’s financial plan anticipates robust growth driven primarily by EndoNu™ sales. Wehave deliberately excluded the introduction of new products or team expansion, as operations are largely outsourced. This projection demonstrates how a lean team can achieve significant revenue with our most advanced product, underlining the sustainability of our business model. Naturally, each potential opportunity discussed above will be evaluated through an updated Business Plan to determine profitability

Revenue Model

Core revenue comes from EndoNu™ sales to distributors ($14/unit). Additional revenue can come from product diversification or services.

Adoption Asumptions : 

Starting in 2026, following FDA clearance, we project conservative adoption based on a business case developed during the FKG–Cementic partnership. Importantly, this forecast treats EndoNu™ as a standard bioceramic sealer and does not account for its unique antimicrobial innovation. For context, the BC sealer launched in 

Pricing & Reimbursement

EndoNu remains at a retail minimum premium price, but it is not prohibitive, with potential for private insurance reimbursement based on clinical value and cost-effectiveness. If we secure insurance reimbursement, EndoNu could become a blockbuster like the dental product Arestin. 

Competitors

Cementic’s first-mover advantage and strong patent position make direct competition unlikely in the short term. Most of R&D department of our comperitior are only focuse on material sciences. We monitor biotech research closely. Our commitment to continuous innovation means that if competitors enter the market, we will likely have advanced formulations ready (e.g., faster healing, combining LNPs with growth factors or orther antiseptic molecules). We may explore partnerships or acquisitions as defensive strategies if a major competitor develops similar solutions. Many alternatives, such as GentleWave, complement rather than rival us. If new methods lower infection rates differently, EndoNu™ would still be valuable for addressing remaining bacteria. We’ll adapt our marketing to position EndoNu™ as part of a comprehensive solution alongside other advancements.

Traction

We have signed an LOI with Henry Shein (US company) and FKG SA (Swiss company).

We are in discussions with Septodont (French company) and Edge Endo (US company).

We have a partnership with Produits Dentaires (Swiss company) and Angelus (Brazilian company).

Due Diligence Docs

Please note that access to the company's confidential materials is limited. Click this button to request access from the Company and its representatives.

Send access request

Supporters

• 
  Mr. Alex Fair, MS
  07/09/2025 - Interested in investing in the project.

Comments

Updates

No updates found .